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1. Introduction   
Approximately 44,000 patients will develop new pancreatic cancers in the US in 2011 and 
38,000 patients will die from the disease (ACS). Prognosis is directly related to the extent of 
tumor. The median survivals for these patients range from 11-18 months for those with 
localized disease, 10-12 months for those with locally advanced disease, and 5-7 months for 
those with metastatic disease, respectively (Evans DBAJ 2011). Although surgical resection 
is the only treatment associated with long-term survival, patients with resectable diseases 
usually account for only 20-25% of cases at diagnosis.  
Despite resection, local regional recurrence and distant metastases occur in up to 50% of 
patients and two-year survival rates range from 20-40% with surgery alone. In 1974, the 
Gastrointestinal Tumor Study Group prospectively randomized patients after curative 
resection of pancreatic adenocarcinoma to adjuvant chemoradiation versus observation. The 
results of this study indicated a doubling of median and quadrupling of long-term survival 
with adjuvant chemoradiation (median, 20 vs. 11 months; 5-year survival, 19% vs. 5%). A US 
Intergroup study compared gemcitabine vs. infusional 5-FU chemotherapy for one month 
prior to and three months after chemoradiation, consisting of continuous infusional 5-FU, as 
adjuvant therapy after pancreatic cancer resection; outcome in those with tumor located in 
the pancreatic head was the primary study endpoint (Regine et al. 2008). The gemcitabine 
plus chemoradiation arm was superior to the 5-FU plus chemoradiation arm, with a median 
survival of 20.6 months vs. 16.9 months and survival at 3-years of 32% vs. 21%. This survival 
advantage came at a cost of appreciable toxicity, with grade 3-4 hematologic and non-
hematologic toxicities occurring in 58% and 58% of subjects, respectively. Oettle et al 
compared gemcitabine given at 1000 mg/m² weekly for 3 of 4 weeks x 6 cycles to no 
additional therapy in 368 patients with resected pancreatic cancer (Oettle et al. 2007). 
Adjuvant gemcitabine was associated with a significant improvement in disease-free 
survival (13.4 vs 6.9 months), and a trend towards improvement in overall survival (median 
22.1 vs 20.2 months); 34% of those receiving gemcitabine were alive at 3 yr vs. 20.5% with 
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surgery alone. Grade 3-4 hematologic and non-hematologic toxicities occurred in fewer than 
5% of subjects receiving gemcitabine.  
While these studies indicate improvement with adjuvant therapy, there is still need to 
improve upon these results. A disadvantage of adjuvant therapy is that as many as 25% of 
patients have their treatment either delayed or forgone due to post-operative complications 
(Yeo CJ 1997; Spitz et al. 1997; Klinkenbijl et al. 1999). In an effort to increase the number of 
patients receiving adjuvant therapy, chemotherapy and radiation therapy can be 
administered pre-operatively (neoadjuvantly) to potential surgical candidates. Additional 
potential benefits of pre-operative therapy include the delivery of therapy to well-
oxygenated tissues, the potential to downstage tumors (particularly when the lesion is 
borderline resectable or unresectable because of regional factors such as tumor involvement 
of the superior mesenteric vein or portal vein, or tumor abutment/encasement of the 
superior mesenteric artery or celiac trunk or gastroduodenal artery up to hepatic artery), 
and the opportunity to observe patients for the development of metastatic disease during 
therapy. After maximal tumor shrinkage and no interval development of metastatic disease, 
surgery can be considered.  
The current standard neoadjuvant regimen includes several months of chemotherapy 
followed by 5 – 6 weeks of radiation therapy concurrent with radiation sensitizing 
chemotherapy, followed by a 4 - 6 week therapy break prior to surgery. This chemoradiation 
regimen is fairly debilitating. ECOG (Pisters et al. 2000) conducted a phase II trial of 
preoperative conventional (50.4 Gy, 1.8 Gy/fraction) chemoradiation, showing that 51% of 
patients had toxicity-related hospital admissions. Treatment-related toxicities were found to 
be proportional to the irradiated volume and radiation dose. At M.D. Anderson, an 
accelerated radiotherapy schedule using 30 Gy in 10 fractions appeared to be more tolerable 
and equally effective (Breslin et al. 2001; Pisters et al. 1998). A recent randomized trial (Bujko 
et al. 2006) has compared preoperative short-course radiotherapy with preoperative 
conventionally fractionated chemoradiation for rectal cancer. The results showed no 
difference in actuarial 4-year overall survival (67.2% in the short-course group vs. 66.2% in 
the chemoradiation group, P = 0.960), disease-free survival (58.4% vs. 55.6%, P = 0.820), and 
crude incidence of local recurrence (9.0% vs. 14.2%, P = 0.170). The study also reported 
similar late toxicity (10.1% vs. 7.1%, P = 0.360) and higher early radiation toxicity in the 
chemoradiation group (18.2% vs. 3.2%, P < 0.001). These data suggest the equivalence in 
efficacy between short course and long course neoadjuvant therapy. Koong et al. (Koong et 
al. 2004) has conducted a phase I study of stereotactic radiosurgery in patients with 
unresectable pancreatic cancer. Fifteen patients were treated at 3 dose levels (3 patients 
received 15 Gy in 1 fraction, 5 patients received 20 Gy in 1 fraction, and 7 patients received 
25 Gy in 1 fraction). No Grade 3 or higher acute GI toxicity was observed. In the 6 evaluable 
patients who received 25 Gy, the median survival was 8 months. All patients in the study 
had local control until death or progressed systemically as the site of first progression. This 
study suggests the feasibility of stereotactic radiosurgery in pancreatic cancer. 
Following the methodology of Koong et al, one can apply the linear-quadratic formulism for 
radiation cell killing to “equate” schemes that vary the dose/fraction and number of 
fractions. This concept of biologically equivalent dose says that the total effect is given by: 

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Where n is the # of fractions and d is the dose/fraction. The “alpha-beta ratio” characterizes 
the radiation response of a particular tissue; a higher value is indicative of a tissue that 
responds acutely to the effects of radiation. Due to their highly proliferative nature, most 
tumors fall into this category. Because prolonging the treatment time introduces a sparing 
(repair) effect in acutely responding tissues, there is significant motivation to deliver 
radiation in larger fractions over a shorter time.  
As the duodenum is in closest proximity to the majority of the pancreatic head tumors, it is 
impossible to avoid treating this structure to a relatively high radiation dose. Koong et al’s 
data suggests that it is possible to irradiate a small volume of duodenum to a dose of 22.5 
Gy in one fraction with acceptable toxicity. While the dose-fractionation scheme employed 
by Koong et al resulted in no significant morbidity, we proposed a phase I study of 
hypofractionated stereotactic body radiotherapy as part of a neoadjuvant regimen in 
patients with locally advanced pancreatic cancer using a more conservative starting dose of 
5 Gy x 5. 
The types of geometric uncertainties that should be considered in stereotactic body 
radiotherapy include tumor motion and patient position (setup error). Discrepancies 
between the actual and planned positions of targets and organs-at-risk during stereotactic 
body radiotherapy can lead to reduced doses to the tumor and/or increased doses to normal 
tissues than planned, potentially reducing the local control probability and/or increasing 
toxicity. Therefore, accurate and precise target localization is critical for hypofractionated 
stereotactic body radiotherapy. Studies found that the bony anatomy is a poor surrogate for 
intraabdominal (Herfarth et al. 2000) and intrathoracic (Guckenberger et al. 2006; Sonke, 
Lebesque, and van Herk 2008) targets. Therefore, direct tumor localization is important. 
Unfortunately, soft tissues are not seen on Exac-Trac (BrainLAB, Heimstetten, Germany) X-
ray images. Thus, fiducial markers for the pancreatic cancer are required. The purpose of the 
current study is to assess daily set-up error using the Exac-Trac system and implanted 
pancreatic fiducial markers during stereotactic body radiotherapy for patients with locally 
advanced pancreatic adenocarcinoma in the current ongoing institutional phase I study and 
to evaluate the effect of body mass index (BMI) on set-up error correction. 
2. Methods 
2.1 Patients 
Included in this study are adult patients (≥ 19 years old) who had a Karnofsky performance 
status of ≥ 60 and underwent stereotactic body radiotherapy planning and treatment 
between October 2008 and February 2011 as part of an institutional research ethics board-
approved study of neoadjuvant hypofractionated stereotactic body radiotherapy following 
chemotherapy in patients with borderline resectable or unresectable pancreatic 
adenocarcinoma. Daily isocenter positioning correction was investigated in 26 patients 
treated with 5 fractions of SBRT for locally advanced pancreatic cancer. Two fiducial 
markers were implanted into the pancreatic head approximately two centimeters apart. 
With daily Exac-Trac images, 3 dimensional couch shifts were made by matching 
corresponding fiducial markers to the digitally reconstructed radiograph from a simulation 
CT scan. BMI was calculated by Weight (kg)/Height2 (m2) and categorized into normal 
weight 18.5 -25 (kg/m2) and overweight/obese >25 (kg/m2). 
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2.2 Stereotactic body radiotherapy planning and treatment  
2.2.1 Patient’s positioning  
The treatment position of the patient was supine, with their arms above their head. The 
immobilization device (Medical Intelligence blue bag) was molded into an immobilizing bed 
for the intended patient’s entire body to make sure that the patients’ position was the same 
during planning, simulation and treatment.  
2.2.2 Patient data acquisition  
A treatment planning free breathing CT scan with IV contrast was required to define tumor, 
clinical, and planning target volumes. A respiratory sorted treatment planning 4D CT scan 
was then acquired with the patient in the same position and immobilized using the same 
device as used for treatment. All tissues to be irradiated were included in the CT scan, with 
a slice thickness of 3 mm. Conventional MRI scans (T1 and T2) were included to assist in 
definition of target volumes. FDG PET-CT, if available, was also included in the treatment 
planning. The Gross Tumor Volume (GTV), Clinical Target Volume (CTV), Planning Target 
Volume (PTV), and organs-at-risk were outlined on all CT slices in which the structures 
exist. 
2.2.3 Volumes 
The GTV was defined as all known gross disease determined from CT, clinical information, 
endoscopic findings, FDG PET-CT and/or conventional MRI. The Integrated Tumor 
Volume based on CT/MRI/PET (GTVfusion) was defined as gross disease on the free 
breathing CT scan, MRI scan and FDG-PET scan. These scans were correlated via image 
fusion technique. The volume was delineated by the treating physician on the above scans 
separately. The GTVCT, GTVMRI and GTVPET (if done) were eventually fused together to 
generate GTVfusion. Patients who had the maximal dimension of the GTVfusion > 8 cm were 
not eligible for the study. The CTV was defined as the GTVs plus areas considered 
containing potential microscopic disease. In this study, we had no intension to treat the 
potential microscopic disease with stereotactic body radiotherapy, therefore the CTV was 
defined as GTVs (i.e. both the primary tumor and the lymph nodes containing clinical or 
radiographic evidence of metastases) plus areas between GTVprimary and GTVlymph nodes. The 
integrated CTV was created with 4D CT information to compensate for internal organ 
motion. The PTV provided a margin around integrated CTV to compensate for the 
variability of treatment set-up. Organs-at-Risk were defined as follows: the skin surface, the 
unspecified tissue (the tissue within the skin surface and outside all other critical normal 
structures and PTVs was designated as unspecified tissue), spinal cord (spinal cord contours 
were defined at least 5 mm larger in the radial dimension than the spinal cord itself, i.e. the 
cord diameter on any given slice was 10 mm larger than the cord itself), duodenum, 
stomach, liver, right kidney, left kidney, small bowels excluding duodenum, and spleen.  
2.2.4 The treatment technique 
The Novalis accelerator (BrainLAB, Heimstetten, Germany) was used to deliver stereotactic 
body radiotherapy. It incorporates stereotactic x-ray capabilities for verifying target 
position. This consists of two floor mounted x-ray tubes and two opposing amorphous 
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silicon flat panel detectors mounted to the ceiling. Each x-ray tube/detector pair is configured 
to image through the linac isocenter with a coronal field of view of approximately 18 cm in 
both the superior-inferior and left-right directions at isocenter. For soft tissue targets, the 
system is designed to be used with radio-opaque platinum markers implanted near the target. 
Two markers, 2 cm away from each other and placed close enough to the target anatomy so 
that they could be observed within the field of view of the x-ray localization system at the time 
of treatment, were implanted prior to CT imaging and treatment planning,. Specific patient 
breathing characteristics were determined during 4D CT. If the breathing pattern was 
adequate, respiratory-gated delivery (turning the beam on only at a specified phase of 
respiration) was used. This method “freezes” target motion and allows reduction of beam 
margins, thereby reducing the amount of irradiated normal tissue. The Novalis system is well 
suited to gated delivery and has been evaluated extensively by Tenn et al (Tenn, Solberg, and 
Medin 2005). The following is a brief procedural summary from that work which is 
incorporated into this study: The patient is set up in the treatment room and infrared reflective 
markers with adhesive bases are attached to their anterior surface so that breathing motion can 
be monitored. A second set of infrared reflective markers is rigidly attached to the treatment 
couch and used as a reference against which the movement of patient markers is measured. 
These rigidly mounted reflectors are also used to track couch location during the patient 
positioning process. The 3D movement of the patient’s anterior surface is tracked via the 
infrared markers and the anterior-posterior component of this trajectory is used to monitor 
breathing motion. The system plots breathing motion versus time and a reference level is 
specified on this breathing trace. This designates the point in the breathing trace at which the 
verification x-ray images will be triggered. The two images are obtained sequentially at the 
instant the breathing trace crosses this level during exhale phase. Because the patient is 
localized based on these images, the gating level is set at the same phase in the breathing cycle 
at which the planning CT data was obtained. Within each image the user locates the positions 
of the implanted markers. From these positions the system reconstructs the 3D geometry of the 
implanted markers and determines the shifts necessary to bring them into alignment with the 
planning CT. The patient is subsequently positioned according to the calculated shifts. Finally, 
a gating window (beam-on region) during which the linac beam will be delivered is selected 
about the reference level. The system can gate the beam in both inhale and exhale phases of the 
breathing cycle. Subsequent x-ray images verifying the location of the implanted markers are 
obtained at the gating level continuously during treatment. If marker positions remain within 
tolerance limits, the target position may also be assumed to be correctly positioned. If they are 
outside the limit, the newly obtained images can be used to reposition the patient and 
maintain treatment accuracy. 
2.2.5 Dose computation 
The treatment plan used for each patient was based on an analysis of the volumetric dose, 
including dose volume histogram (DVH) analyses of the PTV and critical normal structures. 
Treatment planning was accomplished with multiple coplanar conformal beams or arcs to 
allow for a high degree of dose conformality. The uniformity requirement is +10%/-5% of 
the total dose at the prescription point within the tumor volume. The IMRT was used if it 
was of  benefit for decreasing tissue complications. Beam’s Eye View techniques were used 
to select the beam isocenter and direction to fully encompass the target volume while 
minimizing the inclusion of the critical organs in order to select the plan that minimizes the 
dose to normal tissues.  
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2.2.6 Dose specification 
A 5-fraction dose was prescribed. The prescription dose was the isodose which encompasses 
at least 95% of PTV. DVHs were generated for all critical organs-at-risk. The dose to the 
kidneys was carefully monitored and kidney volumes were defined on simulation fields. 
The percent of total kidney volume (defined as the sum of the left and right kidney 
volumes) receiving 15 Gy (3 Gy per fraction) was required to be less than 35% of the total 
kidney volume. The maximum dose to any point within the spinal cord was not allowed to 
exceed 15 Gy (3 Gy per fraction). At least 700 ml or 35% of normal liver was required to 
receive a total dose less than 15 Gy (3 Gy per fraction). The maximum point dose to the 
stomach or small bowel except duodenum could not exceed 60% of prescription dose. An 
isodose distribution of the treatment at the central axis view indicating the position of 
kidneys, liver and spinal cord was required. Dose homogeneity was defined as follows: No 
more than 20% of PTV receive >110% of its prescribed dose; No more than 1% of PTV 
receive <93% of its prescribed dose; No more than 1% or 1 cc of the tissue outside the PTV 
receive >110% of the dose prescribed to the PTV.  
2.2.7 Daily target verification 
The locations of the implanted markers were verified on daily Exac-Trac X-Rays prior to the 
delivery of stereotactic body radiation therapy. 
2.3 Statistical analysis 
For each patient, the mean and standard deviation of daily 3-dimensional position shifts 
(lateral, longitudinal and vertical) were measured. The systematic error (the mean of all 
patients’ means) and the random error (the standard deviation around the systemic error) 
were calculated for daily patient position shifts. The amplitude changes and variability in 
amplitude changes were also measured. Multivariate logistic regression was used to analyze 
the effect of patients’ BMI on patient position changes. All statistical calculations were 
performed using SAS 9.2 (SAS Institute Inc., Cary, North Carolina, USA). 
3. Results 
3.1 Systematic and random daily couch shifts 
A total of 127 treatments from 26 patients were studied. Table 1 provides a summary of the 
systematic and random couch shifts using implanted internal markers. The entire group 
mean (systematic) and standard deviation (random) of the couch shifts from the body 
surface markers are -0.4 ± 5.6 mm, -1.3 ± 6.6 mm and -0.3 ± 4.7 mm in lateral (left-right), 
longitudinal (superior-inferior) and vertical (anterior-posterior) directions, respectively. The 
mean systematic couch shifts > 0 occur in (13/26) 50%, (12/26) 46% and (10/26) 38% in the 
left-right, superior-inferior and anterior-posterior directions, respectively. The mean random 
couch shifts > 5mm occur in (7/26) 27%, (12/26) 46% and (5/26) 19% in the left-right, 
superior-inferior and anterior-posterior directions, respectively. The mean systematic couch 
shifts are significantly smaller than the mean random couch shifts in left-right (-0.3 ± 3.6 mm 
vs. 4.1 ± 2.8 mm, p < 0.0001), superior-inferior (-1.1 ± 4.1 mm vs. 5.5 ± 3.2 mm, p < 0.0001) 
and anterior-posterior (-0.1 ± 3.1 mm vs. 3.5 ± 2.0 mm, p < 0.0001) directions, respectively. 
The couch shifts for the majority of fractions are within ± 10 mm (Figure 1A-1C) 
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 Systematic Error
Mean (mm) ± SD 
Random Error 
Mean (mm) ± SD
P (X2)  
Lateral shift -0.3 ± 3.6 4.1 ± 2.8 <0.0001 
Longitudinal shift -1.1 ± 4.1 5.5 ± 3.2 <0.0001 
Vertical shift -0.1 ± 3.1 3.5 ± 2.0 <0.0001 
Table 1. The averages of systematic and random daily couch shifts three-dimensionally 
 
Fig. 1A. Longitudinal vs. Lateral couch shifts 
 
Fig. 1B. Vertical vs. Longitudinal couch shifts 
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Fig. 1C. Vertical vs. Lateral couch shifts 
3.2 Absolute systematic and random daily couch shifts 
The amplitudes of the systemic and random daily couch shifts are summarized in table 2. 
The mean amplitudes of systematic couch shifts are significantly larger than the mean 
amplitude of random couch shift in left-right (4.1 ± 2.9 mm vs. 2.5 ± 1.3 mm, p = 0.015), 
superior-inferior (5.2 ± 3.1 mm vs. 3.2 ± 1.6 mm, p = 0.007) and anterior-posterior (3.6 ± 1.5 
mm vs. 2.5 ± 1.6 mm, p = 0.016) directions, respectively. The amplitudes of couch shifts in 
the superior-inferior direction are significantly larger than those in the left-right (p = 0.045) 
or anterior-posterior directions (p = 0.001). The absolute couch shifts ≤ 3 mm, ≤ 5 mm and ≤ 
10 mm occur in (51%, 71% and 93%),  (37%, 60% and 87%) and (51%, 73% and 98%) in the 
left-right, superior-inferior and anterior-posterior directions, respectively (Figure 2A-2F). 
There is no correlation among 3 dimensional couch shifts (Figure 3A-3C).  
 
Fig. 2A. Distribution of absolute vertical couch shifts 
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Fig. 2B. Cumulative distribution of absolute vertical couch shifts 
 
Fig. 2C. Distribution of absolute longitudinal couch shifts 
 
Fig. 2D. Cumulative distribution of absolute longitudinal couch shifts 
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Fig. 2E. Distribution of absolute lateral couch shifts 
 
Fig. 2F. Cumulative distribution of absolute lateral couch shifts 
 
 
 
 
Absolute Value 
(Amplitude)  
Systematic Error 
Mean (mm) ± SD 
Random Error  
Mean (mm) ± SD 
P (X2)  
Lateral shift 4.1 ± 2.9 2.5 ± 1.3 0.015  
Longitudinal shift 5.2 ± 3.1 3.2 ± 1.6 0.007 
Vertical shift 3.6 ± 1.6 2.5 ± 1.6 0.016 
 
Table 2. The averages of absolute systematic and random daily couch shifts three-
dimensionally 
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Fig. 3A. Absolute longitudinal vs. absolute lateral couch shifts 
 
Fig. 3B. Absolute vertical vs. absolute lateral couch shifts 
 
Fig. 3C. Absolute vertical vs. absolute longitudinal couch shifts 
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3.3 The magnitude of the pancreatic tumor motion vs. the amplitude of setup 
correction 
Inter-fraction variability in the position of pancreatic tumors is generally considered to be 
resultant from pancreatic breathing motion and patient positioning. We examined the 
association of the magnitude of the changes in the pancreatic tumor breathing motion in 
50% and 80% inhale and exhale with the amplitude of daily setup error correction and 
found no correlation between them (R2≤0.012). (Figure 4A-4C)  
 
Fig. 4A. Relationship between amplitude of respiration and setup correction in the 
longitudinal direction 
 
Fig. 4B. Relationship between amplitude of respiration and setup correction in the lateral 
direction 
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Fig. 4C. Relationship between amplitude of respiration and setup correction in the vertical 
direction 
3.4 The effect of body mass index on daily couch shifts 
The median age for this group of patients is 60 years old (range: 34 -79). Slightly more than 
half of the patients (14/26) are males. The BMIs for this group of patients range between 20 
and 46 with a median value of 27 (kg/m2). There are 8 patients with BMIs of 20-25 and 18 
patients with the BMIs of 26-46. Table 3 shows that there is no difference in daily couch shift 
distribution between these two groups based on BMIs of > 25 or ≤ 25.  
 
 BMI 20-25
N (%)
BMI 26-46 
N (%)
P (X2) 
Lateral systematic shift   0.395 
≤ 0 5 (62.5) 8 (44.4)  
> 0 3 (37.5) 10 (55.6)  
Longitudinal systematic shift   0.793 
≤ 0 4 (50) 10 (55.6)  
> 0 4 (50) 8 (44.4)  
Vertical systematic shift   0.070 
≤ 0 7 (87.5) 9 (50)  
> 0 1 (12.5) 9 (50)  
Lateral random shift   0.418 
≤ 5 mm 5 (62.5) 14 (77.8)  
> 5 mm 3 (37.5) 4 (22.2)  
Longitudinal random shift   0.555 
≤ 5 mm 5 (62.5) 9 (50)  
> 5 mm 3 (37.5) 9 (50)  
Vertical random shift   0.562 
≤ 5 mm 7 (87.5) 14 (77.8)  
> 5 mm 1 (12.5) 4 (22.2)  
Table 3. Distributions of daily couch shifts in patients with body mass indexes of > 25 and ≤ 25  
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Table 4 shows the results of multivariate regression analysis, revealing that patients with a 
BMI ≤ 25 are less likely to have an anterior vertical couch shift from the initial positioning 
(OR: 0.35, 95% CI: 0.16-0.77, p = 0.009) than those with a BMI > 25 after adjusting for age and 
gender, suggesting less correction is needed due to less body relaxation and skin movement 
in patients with a BMI ≤ 25 (kg/m2) than those with a BMI > 25. BMI has no effect on the 
left-right or superior-inferior couch shifts.  
 
BMI 20-25 vs. BMI 26-46  Odd Ratio (95% CI)  P (X2)  
Lateral systematic shift  0.787 (0.371-1.671)  0.533  
Longitudinal systematic shift  1.384 (0.657-2.914)  0.393  
Vertical systematic shift  0.351 (0.160-1.773)  0.009  
Lateral random shift  2.087 (0.333-13.077)  0.432  
Longitudinal random shift  0.606 (0.105-3.513)  0.577  
Vertical random shift  0.501 (0.043-5.838)  0.581  
Table 4. The effect of body mass index on daily couch shifts by multivariate logistic 
regression analysis  
Factors included in the regression models are age, gender and BMI. 
4. Discussion 
Accurate and precise patient positioning at the time of delivering stereotactic body 
radiotherapy is crucial. Image-guided respiratory-gated radiation therapy has been a major 
advancement in minimizing inter- and intra- fractional target variations. To minimize and 
correct for setup uncertainties and inter-fractional motion of extracranial tumors, various 
immobilization and localization techniques have been clinically implemented, including 
transabdominal ultrasonography (Lattanzi et al. 1999; Chandra et al. 2003; Langen et al. 
2003), megavoltage imaging (Schiffner et al. 2007; Serago et al. 2006), kilovoltage imaging 
(Jaffray et al. 1999; Kupelian et al. 2008), use of an in-room computed tomography (CT)–
linear accelerator system (Court et al. 2003; Wong et al. 2005), cone-beam CT (Jaffray et al. 
1999; Kupelian et al. 2008), and placement of internal fiducials (Kupelian et al. 2008; Chen et 
al. 2007; Chung et al. 2004). Pancreatic tumor targets usually exhibit inter-fractional motion 
relative to the bony anatomy because of daily variation in stomach and duodenal filling and 
respiratory patterns. The bony anatomy can be imaged and aligned using in-room 
kilovoltage X-rays; however, with this approach, the position of the pancreatic tumor with 
respect to the bony anatomy is uncertain. Jayachandran et al. has compared the inter-
fractional variation in pancreatic tumor position using bony anatomy to implanted fiducial 
markers and observed substantial residual uncertainty after alignment to bony anatomy 
when irradiating pancreatic tumors using respiratory gating (Jayachandran et al. 2010). 
They reported that bony anatomy matched tumor position in only 20% of the radiation 
treatments. This study evaluates the use of implanted platinum markers in pancreatic cancer 
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patients for daily setup correction. We acquired treatment planning CT scans at least 1 week 
after two fiducial markers were implanted to allow time for inflammation or edema to 
subside. The positions of these markers were then used to guide the daily patient setup 
correction. 
4.1 The magnitude of the inter-fractional setup correction for pancreatic cancer 
In this study, inter-fractional shifts of > 5 mm are observed in 29%, 27% and 40% of fractions 
in left-right, anterior-posterior and superior-inferior directions. When we examined the 
percentage of fractions with the inter-fractional shifts of > 10 mm, we observed only 7% and 
2% in the directions of left-right and anterior-posterior but 13% in the direction of superior-
inferior. The median and maximum couch shifts are 4.2 and 26.2 mm, 3.0  and 20.5 mm and 
3.0 and 18.9 mm in superior-inferior, anterior-posterior and left-right directions, 
respectively. The couch shift in the superior-inferior direction is significantly larger than 
that in the anterior-posterior (p = 0.001) and left-right (p = 0.045) directions. There is no 
difference in couch shifts between anterior-posterior and left-right directions (p = 0.22). 
(Table 5)  
 
Shifts  Median  
(mm) 
Maximum 
(mm)  
≤ 3 mm 
N (%) 
≤ 5 mm  
N (%) 
≤ 10 mm 
N (%) 
T-test 
Left-
Right  
3.0   18.9  65/127 
(51)  
90/127 
(71)  
118/127 
(93)  
SI vs. LR   
p=0.001  
Superior-
Inferior  
4.2  26.2  47/127 
(37)  
76/127 
(60)  
111/127 
(87)  
SI vs. AP   
p=0.045  
Anterior-
Posterior  
3.0   20.5  65/127 
(51)  
93/127 
(73)  
124/127 
(98)  
LR vs. AP  
p=0.216  
Table 5. Comparison of the amplitudes of three-dimensional shifts in median, maximum, 3 
mm, 5 mm and 10 mm. 
There is no correlation in either the direction or the amplitude of couch shifts among all 
three directions. In contrast to our findings, Jayachandran et al. reported that the 
maximum shifts needed in the anterior-posterior, left-right, and superior-inferior 
directions were 9 mm, 13 mm, and 19 mm, respectively when fiducial markers were used 
which are smaller than what we found in the current study (Jayachandran et al. 2010). On 
the other hand, some earlier studies have shown much larger inter-fractional pancreatic 
motions of up to 40 mm (Booth and Zavgorodni 1999; Horst et al. 2002). Allen et al. 
reported a maximum of 17.7 mm inter-fractional setup error in pancreatic cancer using 
daily on line CT scan images (Li et al. 2007). Feng et al. characterized pancreatic tumor 
motion using CINE MRI and found that tumor borders moved much more than expected. 
They indicated that to provide 99% geometric coverage, margins of 20mm inferiorly, 10 
mm anteriorly, 7 mm superiorly, and 4 mm posteriorly are required if respiratory gating 
is not used (Feng et al. 2009). 
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4.2 Relationship between setup correction and amplitude of pancreatic tumor 
breathing motion 
To our knowledge, this is the first study to evaluate the correlation of the amplitude of 
respiration to patient position displacement in pancreatic cancer. We did not find any 
association between the magnitude of the changes in the pancreatic tumor breathing motion 
and the amplitude of daily setup error correction. This is consistent with the results reported 
by Case et al. for liver tumors (Case et al. 2009). 
4.3 Effect of body mass index on setup correction 
This is the first study to examine the influence of BMI on setup correction for pancreatic 
cancer. We observed that patients with a BMI of > 25 have a greater possibility of needing 
vertical setup correction than those with a BMI of ≤ 25. On the other hand, BMI has no effect 
on the setup corrections in superior-inferior and left-right directions. Worm et al reported 
that intrafractional errors for liver and lung cancer were independent of patient‘s BMI 
(Worm et al.). A study on generic planning target margin for rectal cancer treatment setup 
variation did show that BMI was significantly associated with systemic superior-inferior 
(p<0.05) and anterior-posterior (p<0.01) variation and random left-right variation (p<0.05) 
(Robertson, Campbell, and Yan 2009).  
5. Conclusion  
Daily alignment using fiducial markers is an effective method of localizing pancreas 
displacement. It provides the option of reducing margins, thus limiting normal tissue 
toxicity and allowing the possibility of dose escalation for better long-term control. For those 
patients without daily image guided set-up correction, margins of |mean| + 2|standard 
deviation| (11.6 mm, 14.5 mm, and 9.7 mm in left-right, superior-inferior, and anterior-
posterior directions, respectively) should be added to the planning target volume. Patients 
with BMI >25 (kg/m2) may need a larger anterior-posterior margin for planning target 
volume than those with BMI ≤ 25 (kg/m2).  
6. Abbreviations 
US: United States 
ACS: American Cancer Society 
5-FU: 5-Fluorouracil 
ECOG: The Eastern Cooperative Oncology Group 
CT: computed tomography 
4D CT: 4 dimensional computed tomography 
MRI: Magnetic resonance imaging 
FDG PET: fluorodeoxyglucose Positron emission tomography 
GTV: Gross tumor volume 
CTV: Clinical target volume 
PTV: Planning target volume 
DVH: Dose volume histogram 
IMRT: Intensity modulated radiation therapy 
SD: Standard deviation 
BMI: Body mass index 
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